Emergent BioSolutions (NYSE:EBS) Stock Rating Lowered by StockNews.com

Emergent BioSolutions (NYSE:EBS) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Friday.

Several other brokerages have also weighed in on EBS. Benchmark lifted their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Rodman & Renshaw reiterated a “buy” rating and issued a $16.00 target price on shares of Emergent BioSolutions in a research note on Friday, September 13th.

Emergent BioSolutions Stock Up 0.5 %

Shares of NYSE:EBS opened at $8.10 on Friday. Emergent BioSolutions has a 1 year low of $1.42 and a 1 year high of $15.10. The company has a market capitalization of $438.89 million, a PE ratio of -1.98 and a beta of 1.59. The business has a fifty day moving average price of $9.30 and a two-hundred day moving average price of $8.80. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. State Street Corp lifted its holdings in shares of Emergent BioSolutions by 864.7% in the third quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock worth $15,960,000 after buying an additional 1,713,200 shares in the last quarter. Oak Hill Advisors LP purchased a new stake in Emergent BioSolutions in the 3rd quarter worth approximately $9,296,000. American Century Companies Inc. boosted its holdings in Emergent BioSolutions by 240.9% in the 2nd quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock valued at $6,015,000 after purchasing an additional 623,201 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Emergent BioSolutions by 74.5% in the third quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock worth $6,192,000 after purchasing an additional 316,700 shares during the period. Finally, Federated Hermes Inc. raised its position in shares of Emergent BioSolutions by 1,314.0% in the second quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock worth $1,864,000 after buying an additional 253,960 shares in the last quarter. Institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.